유방암 환자의 항암화학요법으로 인한 말초신경병증: 관련요인 및 건강 관련 삶의 질에 미치는 영향
Purpose: This study aimed to identify factors associated with the occurrence of chemotherapy-induced peripheral neuropathy(CIPN) and to study its impact on health-related quality of life (HRQoL) in patients with breast cancer. Methods: In total, 137 women with breast cancer who had undergone more th...
Gespeichert in:
Veröffentlicht in: | Asian oncology nursing 2020, 20(2), , pp.83-91 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | kor |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose: This study aimed to identify factors associated with the occurrence of chemotherapy-induced peripheral neuropathy(CIPN) and to study its impact on health-related quality of life (HRQoL) in patients with breast cancer. Methods: In total, 137 women with breast cancer who had undergone more than one cycle of chemotherapy were recruited for this descriptive study from the outpatient department of a university hospital in Incheon, Korea. Data were collected using a self-reported questionnaire, which included the European Organization for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 and EORTC QLQ-C30. Results: The mean CIPN score between patients was 13.57 on the sensory scale, 15.87 on the motor scale, and 25.06 on the autonomic scale. Of the studied socio-demographic, disease and treatment, and health behavior-related factors, only the chemotherapy regimen was significantly associated with CIPN (t = 2.50, p= .013). Taxane-based chemotherapy was significantly related to higher CIPN scores. Regression analyses revealed that CIPN was a factor that was significantly influential on HRQoL, adjusting for socio-demographic and clinical factors. Conclusion: This study suggests that oncology nurses need to be aware of the increased risk of CIPN in patients with breast cancer undergoing taxane-based chemotherapy. In addition, interventions for alleviating CIPN may be required to improve HRQoL among these patients. KCI Citation Count: 0 |
---|---|
ISSN: | 2287-2434 2287-447X |
DOI: | 10.5388/aon.2020.20.2.83 |